SCHEMBL5368096

SCHEMBL5368096

O=C(O)N1CCC(O)(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 3/20 0.49
OPRM1 P35372 5/20 0.46
HIF1A Q16665 1/20 0.46
CYP3A4 P08684 2/20 0.44
TSHR P16473 1/20 0.44
USP2 O75604 6/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CHRM4 P08173 1/20 0.43
CYP2D6 P10635 1/20 0.42
OPRL1 P41146 5/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRD1 P41143 2/20 0.41
OPRK1 P41145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367535 0.91 S1PR2 (0.57) S1PR2OPRM1HIF1ACYP3A4TSHR
SCHEMBL2925749 0.85 OPRM1 (0.63) OPRM1CYP3A4TSHRCHRM4CYP2D6
SCHEMBL23577913 0.84 OPRL1 (0.53) S1PR2OPRM1TSHROPRL1HPGD
SCHEMBL3330453 0.84 IDO1 (0.43) S1PR2OPRM1CYP3A4CYP2C9CYP2C19
SCHEMBL16319663 0.83 AKR1C3 (0.49) HIF1ACYP3A4TSHRUSP2HSD17B10
SCHEMBL1581880 0.81 OPRL1 (0.50) S1PR2OPRM1CYP3A4TSHROPRL1
SCHEMBL3387449 0.79 S1PR2 (0.43) S1PR2OPRM1CYP3A4CYP2C9CYP2C19
SCHEMBL5375986 0.78 CCR1 (0.42) S1PR2OPRM1CYP3A4CYP2C9CYP2C19
SCHEMBL3820292 0.77 SYK (0.44) S1PR2OPRM1TSHRUSP2CYP2C9
SCHEMBL14748330 0.76 OPRL1 (0.48) S1PR2OPRM1CYP3A4TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 S1PR2 4307/4885OPRM1 3770/4885HIF1A 2782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.